# EDGAR Filing Document

**Accession Number:** 0001946399
**File Stem:** 0001104659-23-009560
**Filing Date:** 2023-2
**Character Count:** 2639
**Document Hash:** 6f348412824b4aca8fe62d8b4b7602f3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-009560.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001104659-23-009560

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230202

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YishengBio Co., Ltd
- **CENTRAL INDEX KEY:** 0001946399
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629
- **BUSINESS PHONE:** 861089202086

**MAIL ADDRESS:**
- **STREET 1:** BUILDING NO. 2, 38 YONGDA ROAD
- **STREET 2:** DAXING BIOMEDICAL INDUSTRY PARK
- **CITY:** DAXING DISTRICT, BEIJING
- **STATE:** F4
- **ZIP:** 102629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** YishengBio Co., Ltd
- **DATE OF NAME CHANGE:** 20220912

February 2, 2023

***<u>Via</u>* <u>EDGAR</u>**

Ms. Li Xiao

Ms. Angela Connell

Mr. Jimmy McNamara

Mr. Jason Drory

U.S. Securities & Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

**Re: YishengBio Co., Ltd (CIK No. 0001946399)** 

**<u>Registration Statement on Form F-4 (File No. 333-269031)</u>**

Dear Ms. Li Xiao, Ms. Connell, Mr. McNamara and Mr. Drory,

Pursuant to Rule 461 of Regulation C ("**Rule 461**") promulgated under the Securities Act of 1933, as amended, YishengBio Co., Ltd (the "**Company**") hereby requests that the effectiveness of the above-referenced registration statement on Form F-4, as amended (the "**F-4 Registration Statement**"), be accelerated to, and that the F-4 Registration Statement become effective at, 4:00 p.m., Eastern Time on February 7, 2023 or as soon thereafter as practicable.

If there is any change in the acceleration request set forth above, the Company will promptly notify you of the change, in which case the Company may be making an oral request of acceleration of the effectiveness of the F-4 Registration Statement in accordance with Rule 461. Such request may be made by an executive officer of the Company or by any attorney from the Company's U.S. counsel, Wilson Sonsini Goodrich & Rosati, Professional Corporation.

*[Signature page follows]*

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| YishengBio Co., Ltd | YishengBio Co., Ltd |
| By: | /s/ Yi Zhang |
| Name: | Yi Zhang |
| Title: | Director and Chairperson |

---